VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC

被引：10

作者：

Hochmair, M. J. ^{[1
]}

Vermaelen, K. ^{[2
]}

Mountzios, G. ^{[3
,4
]}

Carcereny, E. ^{[5
]}

Dooms, C. ^{[6
]}

Lee, S. -h. ^{[7
]}

Morocz, E. M. ^{[8
]}

Kato, T. ^{[9
]}

Ciuleanu, T-e. ^{[10
]}

Dy, G. ^{[11
]}

Parente, M. B. M. C. S. ^{[12
]}

O'Byrne, K. J. ^{[13
]}

Chu, Q. s -c. ^{[14
]}

De Castro Jr, G. ^{[14
]}

Girard, N. ^{[15
]}

Snyder, W. ^{[16
]}

Tran, Q. ^{[16
]}

Kormany, W. ^{[16
]}

Houk, B. ^{[16
]}

Curioni-Fontecedro, A. ^{[17
]}

机构：

[1] Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Klin Florisdorf, Vienna, Austria

[2] UZ Gent Univ Ziekenhuis Gent, Dept Pulm Med, Ghent, Belgium

[3] Henry Dunant Hosp Ctr, Dept Med Oncol 4, Athens 11526, Greece

[4] Henry Dunant Hosp Ctr, Clin Trials Unit, Athens, Greece

[5] Catalan Inst Oncol Badalona, Badalona Appl Res Grp Oncol, Med Oncol, Badalona, Spain

[6] Univ Hosp KU Leuven, Dept Resp Dis, Leuven, Belgium

[7] Sungkyunkwan Univ, Samsung Med Ctr SMC, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea

[8] Pest Cty Hosp Pulmonol, Pulmonolgy, Torokbalint, Hungary

[9] Kanagawa Canc Ctr, Thorac Oncol Dept, Yokohama, Japan

[10] IOCN Oncol Inst Prof Dr Ion Chiricuta, Med Oncol Dept, Cluj Napoca, Romania

[11] Roswell Park Comprehens Canc Ctr, Med Dept, Buffalo, NY USA

[12] CHVNG E Ctr Hosp Vila Nova Gaia Espinho, Unidade 1, Pulmonol, EPE SNS, Porto, Portugal

[13] Princess Alexandra Hosp, Canc Serv, Metro South Hlth, Woolloongabba, Qld, Australia

[14] Univ Alberta, Cross Canc Inst, Med Oncol, Edmonton, AB, Canada

[15] Thorax Inst, Inst Curie, Paris, France

[16] Amgen Inc, Oncol, Thousand Oaks, CA USA

[17] Univ Hosp Zurich, Dept Med Oncol & Hematol, Zurich, Switzerland

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷 / 01期

关键词：

D O I：

10.1016/j.annonc.2023.10.790

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：142 / 144

页数：3

共 50 条

[41] Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT)
Dingemans, Anne-Marie C.
Syrigos, Konstantinos
Livi, Lorenzo
Paulus, Astrid
Kim, Sang-We
Chen, Yuanbin
Felip, Enriqueta
Griesinger, Frank
Ohashi, Kadoaki
Zalcman, Gerard
Hughes, Brett Gordon Maxwell
Sorensen, Jens Benn
Blais, Normand
Ferreira, Carlos G. M.
Lindsay, Colin R.
Dziadziuszko, Rafal
Ward, Patrick J.
Obiozor, Cynthia Chinedu
Wang, Yang
Peters, Solange
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
[42] Characteristics and treatment sequences of patients (pts) with KRAS G12C, other KRAS and non-KRAS advanced or metastatic (AM) non-small cell lung cancer (NSCLC) in the French ESME cohort
Girard, N.
Perol, M.
Debieuvre, D.
Bosquet, L.
Veillard, C.
Caillon, M.
Tzala, L.
Desamericq, G.
Valette, C. Audigier
ANNALS OF ONCOLOGY, 2023, 34
[43] Characteristics and Treatment Sequences of Patients with KRAS G12C, Other KRAS and KRAS-Wild-Type Advanced or Metastatic (AM) Non-Small Cell Lung Cancer (NSCLC) in the French ESME Cohort
Girard, Nicolas
Perol, Maurice
Debieuvre, Didier
Lemonnier, Lydie
Veillard, Charlotte
Caillon, Megane
Tzala, Lia
Desamericq, Gaelle
Audigier-Valette, Clarisse
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 342 - 342
[44] A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Markman, B.
Solomon, B.
Nott, L. M.
Roberts-Thomson, R.
Hughes, B.
Pavlakis, N.
Davis, A.
Brown, L. J.
Parakh, S.
Brungs, D.
Bowyer, S. E.
Nordman, I.
Jennens, R.
Warburton, L.
Harris, S. J.
Samuel, E.
Ramanujam, S.
Wang, A.
Dumas, M.
Gard, G.
ANNALS OF ONCOLOGY, 2023, 34 : S1700 - S1700
[45] Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA)
Zhan, L. J.
Barghout, S.
Raptis, S.
Al-Agha, F.
Popovacki, A.
Esfahanian, N.
Kasymjanova, G.
Proulx-Rocray, F.
Chan, S.
Richardson, M.
Brown, M. C.
Patel, D.
Dean, M. L.
Navani, V.
Moore, E.
Carvery, L.
Yan, E.
Cleary-Gosine, J.
Gibson, A. J.
Hubley, L.
Balaratnam, K.
Ngo, T.
Gill, A.
Black, M.
Sacher, A.
Bradbury, P. A.
Shepherd, F.
Leighl, N.
Cheema, P.
Kuruvilla, S.
Agulnik, J.
Banerji, S.
Juergens, R.
Blais, N.
Cheung, W.
Wheatley-Price, P.
Liu, G.
Snow, S.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S680 - S680
[46] Sotorasib in Advanced KRAS p.G12C-Mutated NSCLC with Treated or Untreated Brain Metastases: Safety and Efficacy Data from the Global Expanded Access Program (EAP)
Awad, M. M.
Pelizzari, G.
Stevenson, J.
Majem, M.
Ferreira, C. Gil
Petty, W.
Arriola, E.
De Castro, J.
Morbeck, I.
Bauman, J.
Toschi, L.
Zer, A.
Metro, G.
Kalmadi, S.
Azkarate, A.
Xia, C.
Meloni, A.
Obiozor, C.
Hsu, H.
Varrieur, T.
Ardito-Abraham, C.
Maimon, N.
Novello, S.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E17 - E17
[47] Trial in progress: A phase III global study of sotorasib, a specific KRAS G12C inhibitor, in combination with panitumumab versus investigator's choice in chemorefractory metastatic colorectal cancer (CodeBreaK 300)
Paez, D.
Meriggi, F.
Cremolini, C.
Folprecht, G.
Korantzis, I.
Chan, E.
Tran, Q.
Fakih, M. G.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S734 - S734
[48] CheckMate 384: Phase IIIb/IV trial of nivolumab (nivo) 480 mg Q4W versus 240 mg Q2W after ≤ 12 months of nivo in previously treated advanced NSCLC.
Garon, Edward B.
Reinmuth, Niels
Falchero, Lionel
Garcia, Yolanda Garcia
Hureaux, Jose
Gore, Ira
Harris, Ronald P.
Bidoli, Paolo
Baldini, Editta
Ros, Silverio
Laack, Eckart
Mitchell, Paul
Wolf, Martin
O'Byrne, Kenneth John
Zibdawi, Labib
Jao, Kevin
Spigel, David
Li, Ang
Rabindran, Sridhar K.
Pichon, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
[49] Heterogeneity and prognostic diagnosis of KRAS-mutated population and KRAS G12C subtype among patients (pts) with advanced NSCLC (aNSCLC): A real-world study aided by machine learning approaches
Loong, H. H. F.
Liu, T.
Pattipaka, T.
Hong, R.
Smith, T. W.
Knoll, S. M.
Pretre, V.
Bitton, R. Caparica
Ye, F.
Farago, A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1088 - S1088
[50] Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)
Barlesi, Fabrice
Felip, Enriqueta
Popat, Sanjay
Solomon, Benjamin J.
Wolf, Juergen
Li, Bob T.
Wu, Yi-Long
Kerr, Keith
Akamatsu, Hiroaki
Camidge, David Ross
Gupta, Ravi G.
Meloni, Alison
Dai, Tian
Borghaei, Hossein
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →